Lower Costs, More Cures Act of 2019

Bill: 116-hr-19
Sponsor: Rep. Walden, Greg [R-OR-2]
Introduced: 2019-12-09 in the House
Policy area: Health
Subjects: Administrative law and regulatory procedures
Administrative remedies
Advisory bodies
Appropriations
Biological and life sciences
Business records
Cancer
Chemistry
Child health
Civil actions and liability
Competition and antitrust
Congressional oversight
Consumer affairs
Corporate finance and management
Cosmetics and personal care
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Executive agency funding and structure
Federal Trade Commission (FTC)
Food and Drug Administration (FDA)
Fraud offenses and financial crimes
Genetics
Government information and archives
Government studies and investigations
Health care costs and insurance
Health information and medical records
Health personnel
Health programs administration and funding
Health technology, devices, supplies
Home and outpatient care
Hospital care
Immunology and vaccination
Income tax deductions
Income tax exclusion
Inflation and prices
Intellectual property
Intergovernmental relations
Judicial review and appeals
Licensing and registrations
Manufacturing
Marketing and advertising
Medicaid
Medical education
Medical research
Medical tests and diagnostic methods
Medicare
Office of the U.S. Trade Representative
Prescription drugs
Product development and innovation
Public participation and lobbying
Research and development
Retail and wholesale trades
State and local government operations
Trade agreements and negotiations
User charges and fees
Women's health

Summary:
action_date: 2019-12-09
text: 

Lower Costs, More Cures Act of 2019

 
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs. 
 
The bill generally
 
 
limits payment amounts for drugs and biologics under Medicare medical services,
 
reduces cost-sharing under the Medicare prescription drug benefit, 
 
modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
 
revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
 
establishes several reporting requirements for drug manufacturers with respect to drug prices.
 


Legislative actions:
action_date: 2019-12-19
text: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
action_date: 2019-12-10
text: Referred to the Subcommittee on Health.
action_date: 2019-12-09
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2019-12-09
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2019-12-09
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2019-12-09
text: Introduced in House
action_date: 2019-12-09
text: Introduced in House